Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Foghorn Therapeutics announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, with CEO Adrian Gottschalk scheduled for a fireside chat on June 9, 2026. The company continues to advance its Gene Traffic Control® platform targeting chromatin regulatory system to develop novel oncology medicines.